Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus |
Domain |
PF01803 LIM-domain binding protein |
Function |
Binds to the LIM domain of a wide variety of LIM domain-containing transcription factors. |
Biological Process |
GO:0001894 tissue homeostasis GO:0001942 hair follicle development GO:0008544 epidermis development GO:0010669 epithelial structure maintenance GO:0019827 stem cell population maintenance GO:0022404 molting cycle process GO:0022405 hair cycle process GO:0035019 somatic stem cell population maintenance GO:0042303 molting cycle GO:0042633 hair cycle GO:0043588 skin development GO:0044089 positive regulation of cellular component biogenesis GO:0048871 multicellular organismal homeostasis GO:0060249 anatomical structure homeostasis GO:0098727 maintenance of cell number GO:0098773 skin epidermis development |
Molecular Function |
GO:0030274 LIM domain binding |
Cellular Component |
GO:0005667 transcription factor complex GO:0031252 cell leading edge |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between LDB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of LDB2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of LDB2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of LDB2 in various data sets.
|
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LDB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LDB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LDB2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LDB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of LDB2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between LDB2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | LDB2 |
Name | LIM domain binding 2 |
Aliases | LDB-2; LIM binding domain 2; LIM domain-binding factor CLIM1; LIM domain-binding factor-2; carboxyl-terminal ...... |
Chromosomal Location | 4p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting LDB2 collected from DrugBank database. |
There is no record. |